77 results
Keyword sustiva Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Sustiva
efavirenz, HIV Infections
Date of authorisation: 28/05/1999, Revision: 46, Authorised, Last updated: 17/10/2022Sustiva Blood-Borne Infections Communicable … Sustiva … Sustiva, INN-efavirenz 30 Churchill … -
List item
Human medicine European public assessment report (EPAR): Efavirenz Teva (updated)
efavirenz, HIV Infections
Date of authorisation: 09/01/2012,
, Revision: 12, Authorised, Last updated: 03/03/2023
European Union (EU) called Sustiva. What is Efavirenz Teva used … to the reference medicine, Sustiva. Two medicines are bioequivalent … and to be bioequivalent to Sustiva. Therefore, the Committee … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2015
CHMP, Last updated: 27/02/2015Sustiva … -
List item
Press release: Updated advice on body fat changes and lactic acidosis with HIV medicines
CHMP, Last updated: 23/10/2015Reyataz, Rezolsta, Stribild, Sustiva, Telzir, Triumeq, Trizivir … Reyataz, Rezolsta, Stribild, Sustiva, Telzir, Triumeq, Trizivir … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015
CHMP, Last updated: 23/10/2015Stocrin: EPAR Stribild: EPAR Sustiva: EPAR Tecfidera: EPAR Telzir … -
List item
Human medicine European public assessment report (EPAR): Stocrin
efavirenz, HIV Infections
Date of authorisation: 28/05/1999, Revision: 48, Authorised, Last updated: 22/02/2023 -
List item
Human medicine European public assessment report (EPAR): Atripla
efavirenz, emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 13/12/2007, Revision: 36, Withdrawn, Last updated: 21/01/2022 -
List item
Human medicine European public assessment report (EPAR): Truvada
emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 20/02/2005, Revision: 46, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Stribild
elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 24/05/2013, Revision: 25, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Eviplera
emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 27/11/2011, Revision: 25, Authorised, Last updated: 13/12/2022 -
List item
Human medicine European public assessment report (EPAR): Edurant
rilpivirine hydrochloride, HIV Infections
Date of authorisation: 28/11/2011, Revision: 20, Authorised, Last updated: 28/10/2022 -
List item
Human medicine European public assessment report (EPAR): Isentress
Raltegravir, HIV Infections
Date of authorisation: 19/12/2007,
, Revision: 42, Authorised, Last updated: 20/10/2022
-
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 November - 1 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 28/11/2022 to 01/12/2022, Last updated: 29/11/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/03/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/202016 4.2.1. Efavirenz – SUSTIVA (CAP), STOCRIN (CAP); NAP … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 March 2018
European Medicines Agency, London, UK, from 05/03/2018 to 08/03/2018, Last updated: 05/03/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 February 2014
European Medicines Agency, London, UK, from 03/02/2014 to 06/02/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 March 2021
European Medicines Agency, Amsterdam, the Netherlands, from 08/03/2021 to 11/03/2021, Last updated: 27/02/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 October 2013
European Medicines Agency, London, UK, from 07/10/2013 to 10/10/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 February 2015
European Medicines Agency, London, UK, from 09/02/2015 to 12/02/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 December 2013
European Medicines Agency, London, UK, from 02/12/2013 to 05/12/2013, Last updated: 02/07/2012 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 October 2015
European Medicines Agency, London, UK, from 19/10/2015 to 22/10/2015, Last updated: 03/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 September 2015
European Medicines Agency, London, UK, from 07/09/2015 to 10/09/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 June 2014
European Medicines Agency, London, UK, from 10/06/2014 to 13/06/2014, Last updated: 13/08/2013 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 May 2014
European Medicines Agency, London, UK, from 19/05/2014 to 22/05/2014, Last updated: 09/08/2013